Department of Paediatrics, Northumbria Healthcare NHS Foundation Trust, Newcastle University, Newcastle upon Tyne, UK.
Acta Paediatr. 2010 Mar;99(3):379-83. doi: 10.1111/j.1651-2227.2009.01630.x. Epub 2009 Dec 3.
The aim of this study was to investigate the acceptability and tolerability of the oral food supplement Neokay for the prevention of vitamin K deficiency bleeding in newborns.
A questionnaire survey was conducted among 45 midwives in which they were asked 10 questions about their use of Neokay, its advantages and disadvantages, and their perceptions of parental attitudes towards this new prophylactic treatment.
During a 6-month period one dose of Neokay was given to 1794 healthy newborns at birth and further daily doses were given to 812 breastfed infants for 3 months. The midwives listed as main advantages ease of administration, no need for prescription or written consent, and transfer of responsibility to parents. As disadvantages, they mentioned possible reduced compliance as a result of the frequency of dosing, decreased parental confidence in breastfeeding and technical issues with packaging.
A prophylactic vitamin K dosage regimen of 1 mg oral vitamin K (Konakion MM Paediatric or Orakay) given to all healthy neonates at birth, combined with daily doses of 50 microg Neokay for 3 months for breastfed babies is well tolerated and acceptable to midwives and parents.
本研究旨在探讨口服食品补充剂 Neokay 预防新生儿维生素 K 缺乏性出血的可接受性和耐受性。
对 45 名助产士进行问卷调查，询问他们关于使用 Neokay 的情况、其优缺点以及他们对父母对此种新预防治疗方法的看法。
在 6 个月期间，在 1794 名健康新生儿出生时给予 Neokay 单剂量，812 名母乳喂养婴儿给予 3 个月的每日剂量。助产士列举的主要优点是给药方便、无需处方或书面同意以及将责任转移给父母。缺点是由于给药频率高，可能会降低顺应性、减少父母对母乳喂养的信心以及包装方面的技术问题。
所有健康新生儿在出生时给予 1 毫克口服维生素 K（Konakion MM 儿科或 Orakay）的预防性维生素 K 剂量方案，与母乳喂养婴儿每日给予 50 微克 Neokay 3 个月的剂量方案相结合，被助产士和父母普遍接受和耐受。
